Skip to main content

Traumatic Brain Injury (TBI)

0
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
AIMN/A1 trial
Active Trials
NCT01779427Withdrawn0Est. Jan 2014
Baxter International
1 program
Hemodynamic ABI MonitorN/A1 trial
Active Trials
NCT06725108Recruiting50Est. Dec 2026
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
divalproex sodiumN/A1 trial
Active Trials
NCT01760785Completed50Est. Jun 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Baxter InternationalHemodynamic ABI Monitor
Oregon TherapeuticsAIM
Colorado Therapeuticsdivalproex sodium

Clinical Trials (3)

Total enrollment: 100 patients across 3 trials

NCT06725108Baxter InternationalHemodynamic ABI Monitor

Hemodynamic ABI Monitor

Start: Dec 2024Est. completion: Dec 202650 patients
N/ARecruiting

Attention Intervention Management

Start: Jan 2013Est. completion: Jan 20140
N/AWithdrawn

Valproate for Mood Swings and Alcohol Use Following Head Injury

Start: Sep 2008Est. completion: Jun 201650 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 100 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.